Premium
Roivant Sciences Ltd (ROIV)
NASDAQ
Hot Features
Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
Roivant Sciences Ltd is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients. Roivant Sciences Ltd is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients.
Namilumab failed to show treatment benefit in patients with pulmonary sarcoidosisFurther development of namilumab for the treatment of sarcoidosis will be discontinued BASEL, Switzerland and...
BASEL, Switzerland and LONDON and NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the second quarter ended September 30, 2024, and...
BASEL, Switzerland and LONDON and NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on...
BASEL, Switzerland and LONDON and NEW YORK, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Organon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their...
VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an additional indication to treat atopic dermatitis Proposed...
Mosliciguat is a potential first-in-class, inhaled soluble Guanylate Cyclase (sGC) activator with targeted delivery to the lungs via once-daily administration, which may have broad applicability...
High dose batoclimab achieved 76% response rate in patients uncontrolled on antithyroid drugs (ATDs) at week 12High dose batoclimab achieved 56% ATD-free response rate in patients uncontrolled on...
BASEL, Switzerland and LONDON and NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the first quarter ended June 30, 2024, and provided...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.665 | -5.57418273261 | 11.93 | 12.2 | 11.22 | 4364777 | 11.70181688 | CS |
| 4 | -0.875 | -7.20757825371 | 12.14 | 12.26 | 11.22 | 5016758 | 11.76840756 | CS |
| 12 | -0.615 | -5.17676767677 | 11.88 | 12.935 | 11.045 | 4584019 | 11.86636393 | CS |
| 26 | 0.555 | 5.18207282913 | 10.71 | 13.055 | 10.04 | 5348723 | 11.69312499 | CS |
| 52 | 0.165 | 1.48648648649 | 11.1 | 13.055 | 9.69 | 5701862 | 11.23002095 | CS |
| 156 | 2.615 | 30.2312138728 | 8.65 | 13.24 | 2.52 | 3777146 | 10.14617367 | CS |
| 260 | 1.765 | 18.5789473684 | 9.5 | 16.76 | 2.52 | 3524484 | 10.13101961 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
